Mumbai, Jan. 27 -- Pharma major, Dr Reddy's Labs on Friday said it has launched Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezo in the U.S. market, following the approval by the US Food and Drug Administration (USFDA).
The Durezo brand and generic had US sales of approximately USD40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA*.
Dr. Reddy's Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.
UNI JS SY
Published by HT Digital Content Services with permission from United News of India....